CyroLife Signs Option to Acquire EndoSpan for up to $450 Million
NYSE-listed CyroLife announced on Wednesday a distribution deal and an option agreement to acquire the Israel-based stent graft company
Founded in 2008 and based in Israeli central town Herzliya, EndoSpan develops stent graft systems for treating aneurysms and dissections throughout the aorta. Its Horizon system for endovascular treatment of abdominal aortic aneurysms is currently in preparations for starting an approval process in Europe. Its Nexus system for treating aortic arch disease has already received a CE Mark (European approval).
Medical procedure (illustration). Photo: Shutterstock
Under the deal, CyroLife will pay EndoSpan $10 million for the European distribution rights for Nexus, and provide up to $15 million in debt financing subject to Endospan's progress in its U.S. clinical trial as its works towards U.S. Food and Drug Administration (FDA) approval. The option agreement gives CyroLife 90 days from the FDA approval to acquire EndoSpan for $350 million plus up to an additional $100 million depending on the commercial success of the system.
